Meet the Team Driving Personalized Cell & Gene Therapy Clinical Development
Worldwide Clinical Trials’ Cell and Gene Therapy Hub partners with you to advance complex programs through clinical development. Our integrated teams bring together scientific, medical, operational, and regulatory expertise to drive success. We take a collaborative, customized approach, leveraging our experience to meet the unique needs of each study. With flexibility and adaptability at our core, we deliver personalized experiences for every sponsor.
Our Strategic and Scientific Leads in our Hub Have:
Meet Your Cell & Gene Therapy Experts
Our team has extensive experience in cell therapy and gene therapy, having delivered studies across North America and Europe that span multiple therapeutic areas and modalities. We leverage this broad expertise to create customized solutions for each sponsor.
Amy Raymond, PhD, PMP
Executive Director, Therapeutic Strategy Lead, Cellular and Genetic Medicines
- 25+ years of drug discovery and development experience and has provided provided strategic support to more than 50 cell and gene therapy studies across Phase I-IV and all therapeutic areas.
- Leads strategic guidance for cell and gene therapy development programs at all stages, especially for programs serving rare and complex diseases.
Virgilio Garcia Lerma
Executive Director, Global Regulatory Strategy
- 20+ years of global clinical research experience.
- Heads the strategic regulatory pre- award team and provides strategic advice on regulatory clinical development for Phase I-IV trials.
Derek Ansel, MS, LCGC
Vice President, Therapeutic Strategy Lead, Rare Disease
- 12+ years in global rare and pediatric clinical research.
- Leads rare disease and pediatric corporate strategy and drives patient-focused advocacy initiatives; board certified genetic counselor.
Michael F. Murphy, MD, PhD
Chief Medical and Scientific Officer
- 30+ years of clinical research experience.
- Co-founder of Worldwide and provides early engagement technical and scientific support relevant to clinical trial methodology and regulatory engagement for collaborative drug development.
Jose Rodriguez Ciancio, MD
Medical Director, Medical Affairs, Immune Mediated & Inflammatory Diseases
- Trained in pediatrics, with MSc in personalized medicine and novel therapies.
- Experience in Phase I-IV global clinical research, leveraging experience in biotech clinical development, as sub-investigator at investigational site and medical monitor in a global CRO.
Juliane K. Mills, MS, MPH
Senior Director, Therapeutic Strategy Lead, Rare Disease
- 23+ years of global clinical research experience.
- Provides operational strategies that are efficient and effective for delivering rare disease trials while being accessible to patients, caregivers, and families.
Dana F. Durst
Executive Director, Site Activation & Regulatory Therapeutic Lead, Oncology
- 16+ years of clinical research experience, including 6+ years in cell and gene therapy development.
- Heads the Global Site Activation Management Team within Worldwide’s Oncology Business Unit, overseeing all aspects of startup activities globally across Phase I-IV programs.
Nathan Chadwick
Senior Director, Therapeutic Strategy Lead, Rare Disease
- 10+ years of Phase I-IV global clinical research experience.
- Champions fit-for-purpose and efficient strategies that incorporate the patient voice.
Jake Boyd
Senior Director, Project Management, Oncology
- 10+ years of Phase I-III clinical research experience, with a primary focus on first-in-human dose-escalation expansion studies.
- 5+ years focused on the development and oversight of cell and gene therapies in both solid tumor and hematology.
Megan Roberts
Director, Project Management, Immune- Mediated & Inflammatory Diseases
- Phase I-III clinical research experience at investigational site and global CROs.
- Specialized in cell therapy development, experience across diverse modalities for rare and complex diseases.
Simran Padam, MD
Medical Director, Medical Affairs, Oncology
- 10+ years of experience in global Phase I first-in-human to Phase III clinical research as a research coordinator, researcher, and medical monitor for academia, CROs, and investigative sites.
- Extensive experience in adoptive cell therapy development programs.
Kunle Oshin, MD
Senior Director, Therapeutic Strategy Lead, Rare Disease
- Trained physician anaesthesiologist with 22+ years of experience in global Phase I-IV clinical research, including 11+ years in project management in multiple therapeutic areas.
- 12+ years of experience in rare disease cell and gene therapy development.
Anthony Poynton
Executive Director, Project Management, Immune-Mediated & Inflammatory Diseases
- Nearly 25 years of global CRO and pharma experience in global Phase I-IV clinical trials.
- Experience working on large, complex studies across several therapeutic areas.
